Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 7, 2008
JNCI Journal of the National Cancer Institute 2008 100(20):1420-1423; doi:10.1093/jnci/djn347
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/20/1420    most recent
djn347v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Howe, L. R.
Right arrow Articles by Lippman, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Howe, L. R.
Right arrow Articles by Lippman, S. M.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

EDITORIALS

Modulation of Breast Cancer Risk by Nonsteroidal Anti-inflammatory Drugs

Louise R. Howe, Scott M. Lippman

Affiliations of authors: Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY (LRH); Departments of Thoracic/Head and Neck Medical Oncology and Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX (SML)

Correspondence to: Scott M. Lippman, MD, Department of Thoracic/Head and Neck Medical Oncology—Unit 432, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009 (e-mail: slippman@mdanderson.org).

The first 10% of the full text of this article appears below.

Nonsteroidal anti-inflammatory drugs (NSAIDs) clearly reduce the risk of human colorectal neoplasia in epidemiological and prospective randomized clinical studies of aspirin and nonaspirin NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, or coxibs (1–3). In contrast, the epidemiological and clinical data on NSAIDs in reducing breast cancer risk are not consistent. This inconsistency is likely attributable to contrasting expression patterns of COX-2, a key target of NSAIDs, in breast and colon neoplasia (4,5), and to differing activities of individual NSAIDs (which have varying selectivity for COX-2 vs COX-1), including a potentially selective impact of certain NSAIDs on hormone receptor–positive breast tumors.

In this issue of the Journal, Takkouche et al. (6) report an extensive meta-analysis (involving 38 studies) supporting an inverse association between NSAID use and risk of breast cancer. They found a statistically significant reduction in . . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Breast Cancer and Use of Nonsteroidal Anti-inflammatory Drugs: A Meta-analysis
Bahi Takkouche, Carlos Regueira-Méndez, and Mahyar Etminan
J Natl Cancer Inst 2008 100: 1439-1447. [Abstract] [Full Text] [PDF]

In This Issue
J Natl Cancer Inst 2008 100: 1417. [Extract] [Full Text] [PDF]